Last reviewed · How we verify
CAIV-T and TIV
CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains.
CAIV-T is a live attenuated influenza vaccine administered intranasally, while TIV is a trivalent inactivated influenza vaccine, both designed to induce immune responses against seasonal influenza strains. Used for Seasonal influenza prevention in pediatric and/or adult populations.
At a glance
| Generic name | CAIV-T and TIV |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CAIV-T (Cold-Adapted Influenza Vaccine - Trivalent) uses temperature-sensitive, live attenuated virus that replicates in the cooler upper respiratory tract to stimulate mucosal and systemic immunity. TIV (Trivalent Inactivated Vaccine) contains inactivated influenza virus particles administered intramuscularly to generate humoral immune responses. The phase 3 comparison likely evaluates relative efficacy, safety, and immunogenicity between these two vaccine modalities.
Approved indications
- Seasonal influenza prevention in pediatric and/or adult populations
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Fever
- Myalgia
- Headache
Key clinical trials
- Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T) (PHASE2)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) (PHASE3)
- Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age (PHASE3)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older (PHASE2)
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants (PHASE1)
- A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children (PHASE2)
- Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (PHASE3)
- Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAIV-T and TIV CI brief — competitive landscape report
- CAIV-T and TIV updates RSS · CI watch RSS
- MedImmune LLC portfolio CI